Navidea Biopharmaceuticals, Inc.
NAVB
$0.0001
$0.000.00%
09/30/2023 | 06/30/2023 | ||||
---|---|---|---|---|---|
Revenue | -- | -- | |||
Total Other Revenue | -- | -- | |||
Total Revenue | -- | -- | |||
Cost of Revenue | -- | -- | |||
Gross Profit | -- | -- | |||
SG&A Expenses | -1.49% | 14.47% | |||
Depreciation & Amortization | -- | -- | |||
Other Operating Expenses | -- | -- | |||
Total Operating Expenses | -12.21% | 0.24% | |||
Operating Income | 12.21% | -0.24% | |||
Income Before Tax | -61.88% | 5.63% | |||
Income Tax Expenses | -- | -- | |||
Earnings from Continuing Operations | -61.88% | 5.63% | |||
Earnings from Discontinued Operations | -- | -- | |||
Extraordinary Item & Accounting Change | -- | -- | |||
Minority Interest in Earnings | -- | -- | |||
Net Income | -137.39% | 508.58% | |||
EBIT | 12.21% | -0.24% | |||
EBITDA | 12.34% | -0.26% | |||
EPS Basic | -118.81% | 367.04% | |||
Normalized Basic EPS | 60.45% | -25.53% | |||
EPS Diluted | -118.81% | 367.04% | |||
Normalized Diluted EPS | 60.45% | -25.53% | |||
Average Basic Shares Outstanding | 105.97% | 47.74% | |||
Average Diluted Shares Outstanding | 105.97% | 47.74% | |||
Dividend Per Share | -- | -- | |||
Payout Ratio | -- | -- |